NYSE:NVTA Invitae - NVTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. $1.29 +0.01 (+0.78%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.22▼$1.3250-Day Range$1.21▼$2.7352-Week Range$1.18▼$9.18Volume5.27 million shsAverage Volume9.99 million shsMarket Capitalization$316.36 millionP/E RatioN/ADividend YieldN/APrice Target$4.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Invitae MarketRank™ ForecastAnalyst RatingHold1.64 Rating ScoreUpside/Downside254.9% Upside$4.58 Price TargetShort InterestBearish17.93% of Shares Sold ShortDividend StrengthN/ASustainability-1.16Upright™ Environmental ScoreNews Sentiment0.23Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.50) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector704th out of 1,005 stocksMedical Laboratories Industry20th out of 26 stocks 2.8 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Hold. The company's average rating score is 1.64, and is based on no buy ratings, 7 hold ratings, and 4 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.58, Invitae has a forecasted upside of 254.9% from its current price of $1.29.Amount of Analyst CoverageInvitae has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.93% of the outstanding shares of Invitae have been sold short.Short Interest Ratio / Days to CoverInvitae has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Invitae has recently increased by 0.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 70.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.16. Previous Next 2.3 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Invitae this week, compared to 3 articles on an average week.Search Interest63 people have searched for NVTA on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.MarketBeat Follows14 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is an increase of 27% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of Invitae is held by insiders.Percentage Held by Institutions76.79% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.50) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Invitae (NYSE:NVTA) StockInvitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.Read More Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comAnalysts Set Invitae Co. (NYSE:NVTA) Target Price at $2.39March 21, 2023 | finance.yahoo.comInvitae Announces Partnership with Epic to Streamline Genetic TestingMarch 26, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 16, 2023 | finance.yahoo.comInvitae Appoints Dr. W. Michael Korn as Chief Medical Officer for OncologyMarch 16, 2023 | americanbankingnews.comInvitae (NYSE:NVTA) Coverage Initiated at StockNews.comMarch 16, 2023 | americanbankingnews.comHead to Head Contrast: Invitae (NYSE:NVTA) versus CannLabs (OTCMKTS:CANL)March 15, 2023 | finance.yahoo.comInvitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic TestingMarch 14, 2023 | finance.yahoo.comInvitae's PCM Assay for Minimal Residual Disease Receives its First Commercial CoverageMarch 26, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 1, 2023 | finance.yahoo.comInvitae to Present at the TD Cowen 43rd Annual Health Care ConferenceFebruary 23, 2023 | finance.yahoo.comDown 78% in 1 Year, Is There Any Hope Left for Invitae?February 16, 2023 | finance.yahoo.comIf You Invested $10,000 in Invitae in 2018, This Is How Much You Would Have TodayFebruary 14, 2023 | finance.yahoo.comInvitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023February 13, 2023 | finance.yahoo.comInvitae Corporation (NVTA) Stock Historical Prices & Data - Yahoo FinanceFebruary 8, 2023 | finance.yahoo.comInvitae Stock: Approach With CautionJanuary 30, 2023 | finance.yahoo.comInvitae Appoints William H. Osborne to its Board of DirectorsJanuary 9, 2023 | finance.yahoo.comInvitae Reports Preliminary 2022 Financial ResultsJanuary 8, 2023 | finance.yahoo.comInvitae to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 21, 2022 | finance.yahoo.comThe one-year earnings decline has likely contributed toInvitae's (NYSE:NVTA) shareholders losses of 89% over that periodDecember 20, 2022 | finance.yahoo.comInvitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.December 7, 2022 | finance.yahoo.comInvitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic ResearchDecember 1, 2022 | finance.yahoo.comInvitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental DiseasesNovember 29, 2022 | finance.yahoo.comIs Invitae in Danger of Running Out of Money?November 15, 2022 | finance.yahoo.comWhy Shares of Invitae Rose 11% on TuesdayNovember 10, 2022 | finance.yahoo.comInvitae Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2022 | finance.yahoo.comWhy Invitae Stock Is Crushing It TodayNovember 9, 2022 | finance.yahoo.comInvitae (NVTA) Q3 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Company Calendar Last Earnings2/28/2023Today3/26/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.58 High Stock Price Forecast$8.50 Low Stock Price Forecast$1.75 Forecasted Upside/Downside+254.9%Consensus RatingHold Rating Score (0-4)1.64 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($13.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-601.64% Pretax Margin-610.34% Return on Equity-59.44% Return on Assets-18.80% Debt Debt-to-Equity Ratio15.68 Current Ratio6.41 Quick Ratio6.13 Sales & Book Value Annual Sales$516.30 million Price / Sales0.61 Cash Flow$8.06 per share Price / Cash Flow0.16 Book Value$0.42 per share Price / Book3.07Miscellaneous Outstanding Shares245,240,000Free Float242,538,000Market Cap$316.36 million OptionableOptionable Beta1.88 Key ExecutivesKenneth D. KnightPresident, Chief Executive Officer & DirectorRoxi WenChief Financial OfficerRobert L. NussbaumChief Medical OfficerThomas R BridaSecretary & Chief Compliance OfficerRobbie EvansChief Strategy OfficerKey CompetitorsCelcuityNASDAQ:CELCBiodesixNASDAQ:BDSXCareDxNASDAQ:CDNASera PrognosticsNASDAQ:SERAPersonalisNASDAQ:PSNLView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 18,569 shares on 3/23/2023Ownership: 0.043%Voya Investment Management LLCBought 5,370 shares on 2/28/2023Ownership: 0.040%Axxcess Wealth Management LLCSold 13,653 shares on 2/16/2023Ownership: 0.014%State of WyomingBought 32,215 shares on 2/16/2023Ownership: 0.013%Point72 Middle East FZEBought 28,661 shares on 2/16/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions NVTA Stock - Frequently Asked Questions Should I buy or sell Invitae stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 4 sell ratings and 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares. View NVTA analyst ratings or view top-rated stocks. What is Invitae's stock price forecast for 2023? 11 Wall Street analysts have issued 12-month price targets for Invitae's shares. Their NVTA share price forecasts range from $1.75 to $8.50. On average, they anticipate the company's stock price to reach $4.58 in the next year. This suggests a possible upside of 254.9% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts. How have NVTA shares performed in 2023? Invitae's stock was trading at $1.86 at the start of the year. Since then, NVTA stock has decreased by 30.6% and is now trading at $1.29. View the best growth stocks for 2023 here. When is Invitae's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our NVTA earnings forecast. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) announced its quarterly earnings results on Tuesday, February, 28th. The medical research company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.21. The medical research company earned $122.45 million during the quarter, compared to the consensus estimate of $120.98 million. Invitae had a negative trailing twelve-month return on equity of 59.44% and a negative net margin of 601.64%. The firm's revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.81) EPS. What ETFs hold Invitae's stock? ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), AXS Green Alpha ETF (NXTE), ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK). What guidance has Invitae issued on next quarter's earnings? Invitae issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00M-, compared to the consensus revenue estimate of $516.11 million. What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? (NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What is Invitae's stock symbol? Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." Who are Invitae's major shareholders? Invitae's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.15%), Sumitomo Mitsui Trust Holdings Inc. (7.10%), Nikko Asset Management Americas Inc. (7.10%), Geode Capital Management LLC (1.76%), Charles Schwab Investment Management Inc. (0.72%) and Gilder Gagnon Howe & Co. LLC (0.62%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen. View institutional ownership trends. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invitae's stock price today? One share of NVTA stock can currently be purchased for approximately $1.29. How much money does Invitae make? Invitae (NYSE:NVTA) has a market capitalization of $316.36 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($13.35) on an earnings per share basis. How many employees does Invitae have? The company employs 1,700 workers across the globe. How can I contact Invitae? Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com. This page (NYSE:NVTA) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.